What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on: October 30,2023 26

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on:October 30,2023 26

α-KG-dependent glycolysis activation by BCAT1 contributes to EGFR-TKI resistance in NSCLC

Updated on: November 28,2024 0

α-KG-dependent glycolysis activation by BCAT1 contributes to EGFR-TKI resistance in NSCLC

Updated on:November 28,2024 0

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on: December 17,2023 10

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on:December 17,2023 10

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on: December 20,2023 10

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on:December 20,2023 10

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on: October 24,2023 4

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on:October 24,2023 4

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

Updated on: December 22,2023 11

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

Updated on:December 22,2023 11

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on: December 20,2023 16

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on:December 20,2023 16

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on: December 20,2023 25

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on:December 20,2023 25

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on: December 22,2023 22

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on:December 22,2023 22

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on: December 21,2023 10

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on:December 21,2023 10

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on: December 21,2023 13

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on:December 21,2023 13

New factor in the development of hereditary kidney cancer discovered

by Gabriele Meseg-Rutzen,University of CologneHira-andFh1-deficient cells promote tumor initiation, growth, and invasion in vivo.(A) Scheme of xenograft injections in the flank of nu

Updated on: December 21,2023 10

New factor in the development of hereditary kidney cancer discovered

by Gabriele Meseg-Rutzen,University of CologneHira-andFh1-deficient cells promote tumor initiation, growth, and invasion in vivo.(A) Scheme of xenograft injections in the flank of nu

Updated on:December 21,2023 10